KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

Pfizer Inc. today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial MONeT, evaluating two doses of ABRYSVO vaccine in ...

By the second half of 2024, Abrysvo had a 48% share in pharmacies and other locations, Pfizer said. Abrysvo sales have pulled ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...

The approval makes Pfizer’s Abrysvo the first RSV vaccine indicated for adults younger than 50, the company said. Photo: Carlo Allegri/REUTERS ...

Pfizer’s RSV vaccine Abrysvo in the manufacturing process. But a rival RSV shot, GSK’s Arexvy, got off to a better start. To catch up, Pfizer overhauled how it packages, ...

NEW YORK, August 12, 2024--Pfizer Inc. ... Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults. Business Wire . Mon, Aug 12, 2024, 6:45 AM 11 min read.

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus.

In August 2023, Pfizer announced that the European Commission granted marketing authorization for ABRYSVO for both adults aged 60 years and older and maternal immunization to help protect infants.

Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) prefusion F ...

Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study ...

Canada NewsWire KIRKLAND, QC, Sept. 19, 2024 KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the ...